(Q35602779)

9 August 2017

1 reference

title

Fibrates for treatment of the metabolic syndrome (English)

1 reference

9 August 2017

1

Kevin C Maki

1 reference

9 August 2017

language of work or name

1 reference

1 January 2004

1 reference

Current Atherosclerosis Reports

9 August 2017

published in

1 reference

9 August 2017

volume

6

1 reference

9 August 2017

issue

1

1 reference

9 August 2017

page(s)

45-51

1 reference

https://scigraph.springernature.com/pub.10.1007/s11883-004-0115-5

9 August 2017

exact match

0 references

cites work

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11883-004-0115-5

Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11883-004-0115-5

Lowering fibrinogen levels: clinical update. BIP Study Group. Bezafibrate Infarction Prevention

21 January 2018

1 reference

12 December 2020

Cardiovascular morbidity and mortality associated with the metabolic syndrome

1 reference

12 December 2020

Metabolic syndrome X: a comprehensive review of the pathophysiology and recommended therapy.

1 reference

12 December 2020

Glycemic index, glycemic load, and risk of type 2 diabetes

1 reference

12 December 2020

Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association

1 reference

12 December 2020

Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia

1 reference

12 December 2020

Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study

1 reference

12 December 2020

Glycemic index: overview of implications in health and disease

1 reference

12 December 2020

The glycemic index: physiological mechanisms relating to obesity, diabetes, and cardiovascular disease

1 reference

12 December 2020

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

1 reference

12 December 2020

Serum homocysteine increases after therapy with fenofibrate or bezafibrate

1 reference

12 December 2020

Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia.

1 reference

12 December 2020

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

1 reference

12 December 2020

Trial of clofibrate in the treatment of ischaemic heart disease. Five-year study by a group of physicians of the Newcastle upon Tyne region

1 reference

12 December 2020

Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey

1 reference

12 December 2020

Bezafibrate in men with lower extremity arterial disease: randomised controlled trial

1 reference

12 December 2020

Effects of fibric acid derivatives on biliary lipid composition

1 reference

12 December 2020

A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators

1 reference

12 December 2020

Effects of fibrates on serum metabolic parameters.

1 reference

12 December 2020

Modulation of plasma fibrinogen levels by ciprofibrate and gemfibrozil in primary hyperlipidaemia

1 reference

12 December 2020

Ischaemic heart disease: a secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians

1 reference

12 December 2020

Effect of ciprofibrate on C-reactive protein and fibrinogen levels

1 reference

12 December 2020

Dietary glycemic load assessed by food-frequency questionnaire in relation to plasma high-density-lipoprotein cholesterol and fasting plasma triacylglycerols in postmenopausal women

1 reference

12 December 2020

Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial

1 reference

12 December 2020

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

1 reference

12 December 2020

Clofibrate and niacin in coronary heart disease

1 reference

12 December 2020

The role of fibric acids in atherosclerosis

1 reference

12 December 2020

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

1 reference

12 December 2020

Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate

1 reference

12 December 2020

Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group

1 reference

12 December 2020

Effect of insulin resistance and hyperglycemia on proinsulin release in a primate model of diabetes mellitus

1 reference

12 December 2020

Overview of fenofibrate

1 reference

12 December 2020

High carbohydrate diets, triglyceride-rich lipoproteins, and coronary heart disease risk.

1 reference

12 December 2020

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

12 December 2020

Rhabdomyolysis after taking atorvastatin with gemfibrozil

1 reference

12 December 2020

Metabolic advantages of spreading the nutrient load: effects of increased meal frequency in non-insulin-dependent diabetes

1 reference

12 December 2020

Insulin resistance/compensatory hyperinsulinemia, essential hypertension, and cardiovascular disease

1 reference

12 December 2020

Fibrates, dyslipoproteinaemia and cardiovascular disease

1 reference

12 December 2020

Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam.

1 reference

12 December 2020

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

12 December 2020

Prevalence and Trends in Obesity Among US Adults, 1999-2000

1 reference

12 December 2020

Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment

1 reference

12 December 2020

Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?

1 reference

12 December 2020

Improvement of fibrinolysis and plasma lipoprotein levels induced by gemfibrozil in hypertriglyceridemia

1 reference

12 December 2020

Effects of gemfibrozil on insulin sensitivity and on haemostatic variables in hypertriglyceridemic patients

1 reference

12 December 2020

Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients

1 reference

12 December 2020

10.1007/S11883-004-0115-5

Identifiers

DOI

1 reference

9 August 2017

1 reference